Sepsis Research Analysis
December’s sepsis research converged on precision, with phenotype-guided immunotherapy (ImmunoSep, JAMA) improving early organ dysfunction and multi-omic/AI frameworks sharpening stratification. Mechanistic advances spotlighted endothelial injury and protection: a DLL4–Notch1 neutrophil–endothelium axis driving PANoptosis in septic lung injury, ferroptosis resistance via the Piezo1–BHLHE40–SLC7A11 pathway, and an immunothrombosis IFNβ–MALAT1–caspase-11 axis predicting early DIC. Cardiac protecti
Summary
December’s sepsis research converged on precision, with phenotype-guided immunotherapy (ImmunoSep, JAMA) improving early organ dysfunction and multi-omic/AI frameworks sharpening stratification. Mechanistic advances spotlighted endothelial injury and protection: a DLL4–Notch1 neutrophil–endothelium axis driving PANoptosis in septic lung injury, ferroptosis resistance via the Piezo1–BHLHE40–SLC7A11 pathway, and an immunothrombosis IFNβ–MALAT1–caspase-11 axis predicting early DIC. Cardiac protection emerged from identifying heme as a STING ligand that accelerates endothelial senescence, nominating heme scavenging and STING blockade. Diagnostic momentum included admission IFNβ for early DIC risk and a rapid host transcriptomic signature that detects antibiotic response within 24 hours, pointing toward earlier de-escalation and biomarker-enriched trials.
Selected Articles
1. DLL4+ neutrophils promote Notch1-mediated endothelial PANoptosis to exacerbate acute lung injury in sepsis.
A DLL4+ neutrophil subset induced by eCIRP engages endothelial Notch1 to trigger ZBP1-driven PANoptosis in pulmonary endothelium, worsening sepsis-associated ALI. A Notch1-derived inhibitory peptide (NDI) blocked DLL4–Notch1 interaction, reduced endothelial PANoptosis and vascular leak, and improved survival in preclinical models.
Impact: Reveals a druggable neutrophil–endothelial interaction that directly links innate immune heterogeneity to endothelial cell death, with a bespoke peptide conferring survival benefit in vivo.
Clinical Implications: Targeting Notch1–DLL4 could prevent or attenuate sepsis-induced ALI by preserving endothelial integrity; supports early-phase testing of NDI-like agents after safety/PK confirmation.
Key Findings
- eCIRP induces DLL4+ neutrophils that bind endothelial Notch1 and trigger ZBP1-driven PANoptosis.
- Blocking DLL4–Notch1 reduces endothelial PANoptosis, vascular permeability, and inflammatory markers.
- NDI improved survival in preclinical sepsis lung injury models.
2. Heme drives cardiac endothelial senescence in sepsis via STING activation.
Heme accumulation in sepsis directly activates STING, promoting cardiac endothelial senescence and impairing cardiac recovery. STING inhibition and heme scavenging with hemopexin reduced endothelial senescence and improved cardiac outcomes in septic mice.
Impact: Uncovers a tractable heme–STING–senescence pathway linking hemolysis to septic cardiomyopathy, nominating STING inhibitors and heme scavengers for translation.
Clinical Implications: Supports biomarker development for heme/STING activity and evaluation of hemopexin or STING blockade to protect cardiac endothelium and recovery in sepsis.
Key Findings
- Cardiac endothelial cells are the predominant senescent population in septic hearts.
- Heme acts as a novel STING ligand driving endothelial senescence.
- STING inhibition or heme clearance improved cardiac recovery in septic mice.
3. A Critical Role for MALAT1 in Gram-negative Bacteria-induced Coagulation via Regulation of Caspase-11 signaling.
Admission plasma IFNβ predicted 48-hour onset of septic DIC and mechanistically induced macrophage MALAT1, which suppressed GPX4, promoted caspase-11 activation and GSDMD-dependent PS exposure, and drove immunocoagulation. Macrophage-specific Malat1 deletion restored GPX4 and protected against bacteria-induced coagulation.
Impact: Bridges a bedside biomarker (IFNβ) with a causal macrophage lncRNA mechanism (MALAT1–GPX4–caspase-11), providing both prognostic utility and therapeutic targets for early coagulopathy.
Clinical Implications: Validating admission IFNβ could enable early DIC risk stratification and trial enrichment; MALAT1 inhibition or GPX4-restoring strategies may mitigate caspase-11–driven immunothrombosis.
Key Findings
- Admission IFNβ correlates with 48-hour septic DIC onset; HMGB1 does not.
- IFNβ induces macrophage MALAT1, suppressing GPX4 and promoting caspase-11 activation and PS exposure.
- Macrophage-specific Malat1 deletion protects against bacteria-induced coagulation.
4. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
In a multicountry, double-blind RCT (n=276), immune-phenotype–matched therapy (anakinra or IFN-γ) improved the primary organ-dysfunction endpoint versus placebo, though 28-day mortality was not significantly reduced; safety signals included anemia with anakinra and bleeding with IFN-γ.
Impact: Landmark clinical evidence that objective immune endotyping can direct therapy and modify organ dysfunction, providing a practicable precision-care pathway.
Clinical Implications: Supports early immune phenotyping (e.g., ferritin, monocyte HLA-DR) to select candidates for targeted therapy; motivates larger mortality-powered trials and focused safety monitoring.
Key Findings
- Phenotype-guided therapy achieved day-9 SOFA response (35.1% vs 17.9%, P=.002).
- No significant 28-day mortality reduction despite organ improvement.
- Serious TEAEs were common; anemia with anakinra, hemorrhage with IFN-γ.
5. Endothelial mechanosensitive transcription factor BHLHE40 induced by Piezo1 suppresses endothelial ferroptosis and inflammation via SLC7A11.
A Piezo1→Ca2+/calcineurin→NFAT2–HDAC1→BHLHE40 cascade upregulates SLC7A11, boosts cystine import, and confers ferroptosis resistance in endothelium. Endothelial BHLHE40 overexpression attenuated lung vascular leak, neutrophil infiltration, and cytokine release in vivo.
Impact: Introduces an in vivo–validated mechanotransduction pathway that protects endothelium from ferroptosis, complementing other host-directed strategies in sepsis.
Clinical Implications: Highlights druggable nodes (e.g., SLC7A11, Piezo1 pathway modulators) and motivates biomarker development for endothelial ferroptosis to guide vascular-protective therapies.
Key Findings
- Shear stress activates Piezo1 leading to NFAT2–HDAC1–BHLHE40 induction.
- BHLHE40 upregulates SLC7A11, reduces ROS/lipid peroxidation, and confers ferroptosis resistance.
- Endothelial BHLHE40 overexpression mitigates LPS-induced lung injury features in vivo.